EyePoint Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jay S. Duker
- Full Time Employees
- 214
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 480 Pleasant Street Watertown MA United States of America 02472
- IPO Date
- Jan 27, 2005
- CIK
- 0001314102
- Website
- eyepoint.bio
- Similar Companies
- Business
- EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) develops and commercializes innovative therapeutics for serious retinal diseases using its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery; its lead product candidate DURAVYU (EYP-1901) combines vorolanib, a selective tyrosine kinase inhibitor, for VEGF-mediated conditions including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with prior Durasert formulations supporting four FDA-approved products administered to thousands of patients. Founded in 1987 and headquartered in Watertown, Massachusetts, with a manufacturing facility in Northbridge, Massachusetts, the clinical-stage biopharmaceutical company targets ophthalmology markets in the US and globally through Phase 3 pivotal trials. Recently, EyePoint completed enrollment in the Phase 3 LUGANO and LUCIA trials for DURAVYU in wet AMD involving over 900 patients, with topline data from LUGANO expected mid-2026; initiated the pivotal Phase 3 DME program with COMO and CAPRI trials following FDA alignment on a non-inferiority pathway, first dosing anticipated Q1 2026; presented preclinical data at AAO 2025 showing DURAVYU reduces IL-6 mediated inflammation by over 50% via JAK-1 inhibition alongside VEGF blockade; and raised $172.5 million in an oversubscribed October 2025 public offering to fund the DME program and extend cash runway into Q4 2027.
Company News
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, GitLab, GLOBAL FOUNDRIES, Martin Marietta Materials, Rocket Lab USA, Strategy, Toast, Tower Semiconductor, and More
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT